利妥昔单抗治疗天疱疮后预测临床复发的生物标志物
该回顾性队列研究纳入62例天疱疮患者共99个利妥昔单抗治疗周期,纵向分析CD19+ B细胞、CD4+ T细胞及Dsg1/Dsg3自身抗体水平。复发与B细胞重建、低CD4+ T细胞计数及Dsg1/Dsg3检测阳性相关。
要点
- B细胞重建前复发罕见;低CD4计数(<400 cells/μL)预测复发。
- Dsg1>20 IU预测皮肤黏膜型复发(HR 6.40)。
- Dsg3>20 IU预测黏膜及皮肤黏膜型复发(HR 32.92)。
核心结论
- 复发与B细胞重建、低CD4+ T细胞计数及Dsg1和Dsg3检测阳性相关。
研究设计与样本
- 回顾性队列研究,纳入62例天疱疮患者共99个利妥昔单抗治疗周期,提供纵向临床评分和生物标志物数据,应用扩展时间变异Kaplan-Meier估计和扩展Cox模型。
主要发现
- B细胞重建前复发罕见;单因素分析显示低CD4计数(<400 cells/μL)预测复发(P < .001)。
- 皮肤黏膜型患者中Dsg1>20 IU预测复发(风险比6.40;P = .019);黏膜及皮肤黏膜型患者中Dsg3>20 IU预测复发(风险比32.92;P < .001)。
- 多因素分析显示CD4每增加200,复发风险比降低35%(P = .029);皮肤黏膜型患者Dsg1阳性使复发风险增加12.32倍(P = .001);黏膜及皮肤黏膜型患者Dsg3阳性使复发风险增加28.38倍(P = .006)。
关键数值与推荐
- 低CD4计数定义为<400 cells/μL。
- Dsg1和Dsg3阳性定义为>20 IU。
临床怎么用
- 监测B细胞重建、CD4+ T细胞计数及Dsg1/Dsg3抗体水平有助于预测天疱疮复发。
局限性
- 回顾性设计且随访不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rituximab is an effective therapy for pemphigus, although relapses are common. OBJECTIVE: To identify biomarkers to predict relapse of pemphigus following rituximab treatment. METHODS: In this retrospective cohort study, 62 patients with pemphigus treated with 99 rituximab cycles provided longitudinal clinical scoring and biomarker data, including levels of CD19+ B cells, CD4+ T cells, and desmoglein 1 (Dsg1) and desmoglein 3 (Dsg3) autoantibodies. An extended time-variant Kaplan-Meier estimator and extended Cox model were applied. RESULTS: Relapse was rare before B-cell repopulation. Univariate analysis revealed low CD4 count (<400 cells/μL) to predict relapse (P < .001). A positive result of testing for Dsg1 (>20 IU) was predictive of relapse among patients with mucocutaneous disease (hazard ratio, 6.40; P = .019); a positive result of testing for Dsg3 (>20 IU) was predictive in patients with mucocutaneous and mucosal disease (hazard ratio, 32.92; P < .001). Multivariable analysis revealed that every CD4 value increase of 200 decreases the hazard ratio for relapse by 35% (P = .029). A positive result of testing for Dsg1 increases the risk for relapse by a factor of 12.32 in patients with mucocutaneous disease (P = .001); positive result of testing for Dsg3 increases risk for relapse by 28.38 in patients with mucosal and mucocutaneous disease (P = .006). LIMITATIONS: Limitations include the retrospective design and inconsistent follow-up. CONCLUSION: Relapse is associated with B-cell repopulation, low CD4+ T -cell count, and positive result of testing for Dsg1 and Dsg3.
引用
- Albers LN, Liu Y, Bo N, et al. Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab. J Am Acad Dermatol. 2017. PMID: 28927663. doi:10.1016/j.jaad.2017.07.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。